TY - JOUR
T1 - Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV
AU - Lokugamage, Kumari G.
AU - Yoshikawa-Iwata, Naoko
AU - Ito, Naoto
AU - Watts, Douglas M.
AU - Wyde, Philip R.
AU - Wang, Nan
AU - Newman, Patrick
AU - Kent Tseng, Chien Te
AU - Peters, C. J.
AU - Makino, Shinji
N1 - Funding Information:
This work was supported by National Institutes of Health Service Contract AI 65298 and grants AI29984 and AI72493. NI was supported by a fellowship for long-term overseas research for young investigators sponsored by the Ministry of Education, Culture, Sports, Science and Technology, Japan.
PY - 2008/2/6
Y1 - 2008/2/6
N2 - We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.
AB - We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.
KW - Mouse
KW - Neutralizing antibody
KW - SARS coronavirus
KW - Virus-like particles
UR - http://www.scopus.com/inward/record.url?scp=38349038213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349038213&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.11.092
DO - 10.1016/j.vaccine.2007.11.092
M3 - Article
C2 - 18191004
AN - SCOPUS:38349038213
SN - 0264-410X
VL - 26
SP - 797
EP - 808
JO - Vaccine
JF - Vaccine
IS - 6
ER -